Gallant
PrivateLast Round
Series B
Jun 30, 2025
Total Funding Raised
$51M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Gallant operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in June 2025.
Gallant is a biotechnology company that develops a pet health technology platform providing stem cell therapy and regenerative medicine to treat diseases in companion animals.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gallant Comparables
Compare Gallant with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| StemcellX | 86% | |
| Animal Cell Therapies, Inc. | 84% | |
| VetStem Biopharma | 84% |
For institutional investors. Book with your work email.
Gallant Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 30, 2025 | ||||
| Series A | Jan 8, 2024 | ||||
| Seed | Oct 24, 2019 | ||||
| Seed | Aug 5, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Gallant Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Slow Ventures | Seed |
| Maveron | Seed |
| Digitalis Ventures | Series A, Series B |
| Hill Creek Capital | Series A, Series B |
| Science Inc. | Seed |
| BOLD Capital Partners | Seed, Series B, Series A |
| NovaQuest Capital Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2026
Dechra to acquire cell-therapy platform for pet diseases.
- Nov 10, 2026
Dechra has agreed to acquire the cell-therapy platform.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- sells_assets_toNov 10, 2026
Gallant agrees to sell its cell-therapy platform to Dechra on Nov 9th '26 for undisclosed terms, with completion subject to customary closing conditions.
- is_developingNov 10, 2026
Gallant develops investigational ready-to-use cell therapies for dogs and cats, including treatments targeting feline chronic gingivostomatitis, osteoarthritis, feline chronic kidney disease, and canine atopic dermatitis.
For institutional investors. Book with your work email.
Gallant Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Gallant's valuation, stock price, and market status.
Is Gallant a public or private company?
Gallant is a private company.
What is the current stock price of Gallant?
Gallant is a private company, so its shares have no public market price. Caplight tracks Gallant's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Gallant worth (valuation)?
Valuation information for Gallant is not publicly available.
Can I buy Gallant stock?
Gallant shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Gallant's last funding round?
Gallant's most recent funding round was Series B on June 30, 2025.
Who are the main investors in Gallant?
Key investors in Gallant include Digitalis Ventures, BOLD Capital Partners, Bold Capital.
Will Gallant IPO soon?
No public IPO plans have been announced for Gallant.
How can I track Gallant secondary market activity?
Caplight tracks bids, offers, and trades in Gallant's shares on secondary markets.